Literature DB >> 9451711

Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

G Huether1, D Zhou, E Rüther.   

Abstract

The massive and prolonged stimulation of serotonin (5-HT)-release and the increased dopaminergic activity are responsible for the acute psychomimetic and psychostimulatory effects of 3,4-methylenedioxy-methamphetamine (MDMA, "ecstasy") and its congeners. In vulnerable subjects, at high doses or repeated use, and under certain unfavorable conditions (crowding, high ambient temperature), severe, in some cases fatal, averse systemic reactions (hyperthermia, serotonin-syndrome) may occur during the first few hours. Animal experiments revealed the existence of similar differences in vulnerability and similar dose- and context-related influences on a similar sequence of acute responses. The severity of these acute systemic responses is closely related to the severity of the long-term damage to 5-HT axon terminals caused by the administration of substituted amphetamines. Attempts to identify the mechanisms involved in this selective degeneration of 5-HT presynapses brought to light a multitude of different factors and conditions which either attenuate or potentiate the loss of 5-HT terminals caused by MDMA and related amphetamine derivatives. These puzzling observations suggest that the degeneration of 5-HT presynapses represents only the final step in a sequence of events which compromise the ability of 5-HT terminals to maintain their functional and structural integrity. Substituted amphetamines selectively tax energy metabolism in 5-HT presynapses through their ability to exchange with 5-HT and to dissipate transmembrane ion gradients. The active carrier systems in the vesicular and presynaptic membrane operate at a permanently activated state. The resulting energy deficit can no longer adequately restored by the 5-HT presynapses when their availability of substrates for ATP production is additionally reduced by the hyperthermic and other energy consuming reactions which are elicited by the systemic administration of substituted amphetamines. The exhaustion of energy in 5-HT nerve terminals compromised all energy-requiring endogenous mechanisms involved in the regulation of transmembrane-ion exchange, internal Ca(++)-homeostasis, prevention of oxidative stress, detoxification, and repair. Above a critical threshold the failure of these self-protective mechanisms will lead to the degeneration of the 5-HT axon terminals. Based on the role of 5-HT as a global modulatory transmitter-system involved in the stabilization and integration of impulse flow between distributed multifocal neuronal networks, the partial loss of 5-HT presynapses must be expected to impair the ability of these networks to maintain the integrity of signal flow pattern, and increase the likelihood of switching to unstable information processing. Behavioral responding may therefore become more dominated by activities generated in individual networks, and hitherto "buffered" personality traits and predisposition may become manifested as defined psychiatric syndromes in certain predisposed subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9451711     DOI: 10.1007/BF01285547

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  142 in total

Review 1.  MDMA: historical perspectives.

Authors:  J W Gibb; M Johnson; D Stone; G R Hanson
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate.

Authors:  W Slikker; R R Holson; S F Ali; M G Kolta; M G Paule; A C Scallet; D E McMillan; J R Bailey; J S Hong; F M Scalzo
Journal:  Neurotoxicology       Date:  1989       Impact factor: 4.294

3.  The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Authors:  K T Finnegan; J J Skratt; I Irwin; J W Langston
Journal:  Neurosci Lett       Date:  1989-11-06       Impact factor: 3.046

Review 4.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

5.  L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.

Authors:  C J Schmidt; C K Black; V L Taylor
Journal:  Eur J Pharmacol       Date:  1991-10-02       Impact factor: 4.432

Review 6.  Amphetamine: effects on catecholamine systems and behavior.

Authors:  L S Seiden; K E Sabol; G A Ricaurte
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

7.  Effects of p-chloroamphetamine on brain serotonin in immature rats.

Authors:  J A Clemens; R W Fuller; K W Perry; B D Sawyer
Journal:  Commun Psychopharmacol       Date:  1978

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine.

Authors:  U V Berger; X F Gu; E C Azmitia
Journal:  Eur J Pharmacol       Date:  1992-05-14       Impact factor: 4.432

10.  Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems.

Authors:  M Johnson; I Elayan; G R Hanson; R L Foltz; J W Gibb; H K Lim
Journal:  J Pharmacol Exp Ther       Date:  1992-05       Impact factor: 4.030

View more
  16 in total

1.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

Review 2.  Serotonergic dysfunction: brain imaging and behavioral correlates.

Authors:  Jana Wrase; Matthias Reimold; Imke Puls; Thorsten Kienast; Andreas Heinz
Journal:  Cogn Affect Behav Neurosci       Date:  2006-03       Impact factor: 3.282

Review 3.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

4.  A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain.

Authors:  M I Colado; J Camarero; A O Mechan; V Sanchez; B Esteban; J M Elliott; A R Green
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine.

Authors:  Dawn E Muskiewicz; Federico Resendiz-Gutierrez; Omar Issa; F Scott Hall
Journal:  Pharmacol Biochem Behav       Date:  2020-02-12       Impact factor: 3.533

6.  Effect of sulpiride on the amphetamine-induced changes in extracellular dopamine, DOPAC, and hydroxyl radical generation in the rat striatum.

Authors:  Elmira Anderzhanova; Kirill S Rayevsky; Pirjo Saransaari; Simo S Oja
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 7.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

Review 8.  Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2009-11-05       Impact factor: 2.328

9.  Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.

Authors:  A C Parrott; J Lock; A C Conner; C Kissling; J Thome
Journal:  Neuropsychobiology       Date:  2008-07-24       Impact factor: 2.328

10.  White-matter abnormalities in brain during early abstinence from methamphetamine abuse.

Authors:  Marc C Tobias; Joseph O'Neill; Matthew Hudkins; George Bartzokis; Andrew C Dean; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2010-01-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.